Expert Analysis

Clinical Updates in HBV Treatment

Source: CCO Independent Conference Coverage of the 2007 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Clinical Updates in HBV Treatment

Faculty:

Emmet B. Keeffe, MD, MACP
Fred Poordad, MD
Paul Martin, MD

CME CREDIT INFORMATION

Release Date: 01/09/08

Expiration Date: 01/08/09

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.4 Nursing CE credits

Pharmacists: 1.4 contact hours (0.14 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the results of recent studies on HBV and its associated complications, including hepatocellular carcinoma
Discuss results of clinical studies of approved and investigational treatments for chronic HBV
Recount strategies for managing patients with drug-resistant HBV

Topics covered include:

REVEAL Analyses: Predictive Value of HBV DNA Levels Over Time in Predicting Hepatocellular Carcinoma
Predictive Value of HBV Genotype and Subgenotype in Predicting Hepatocellular Carcinoma
Correlation Between Serial HBV DNA Measurements and Long-term Histologic Outcome
GLOBE Subanalysis: Baseline and On-Treatment Predictors of Efficacy Outcomes at 2 Years
Tenofovir vs Adefovir in HBeAg-Negative and HBeAg-Positive Patients
ETV-901: Long-term Efficacy and Safety of Entecavir in HBeAg-Positive Patients
HBsAg Seroconversion Rates and Long-Term Outcomes in HBeAg-Positive Patients Treated With Standard Interferon
Benefits of Using Nucleos(t)ide Analogues in Patients With HBV-Related Acute Liver Failure
Antiviral Usage Patterns Drive Patterns of Resistance in the United States
Efficacy of Tenofovir in Lamivudine- and Adefovir-Experienced Patients
Suboptimal Entecavir Response in Patients With a Suboptimal Response to Adefovir
ETV-901 Subanalysis: Long-term Responses in Prior Protocol-Defined Nonresponders

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.